Breast health
Top breast concerns in menopause — References & further reading
1 Ravdin, P., et al. 2007. The decrease in breast-cancer incidence in 2003 in the United States. NEJM, 356 (16), 1670–1674. URL: http://content.nejm.org/cgi/content/full/356/16/1670 (accessed 09.11.2009).
NIH | National Cancer Institute. 2007. Decrease in breast cancer rates related to reduction in use of hormone replacement therapy. URL: http://www.nih.gov/news/pr/apr2007/nci-18a.htm (accessed 09.11.2009).
Kolata, G. 2006. Hormones and cancer: Assessing the risks. NYT. URL: http://query.nytimes.com/gst/fullpage.html (accessed 09.18.2009).
2 [British Medical Journal.] 2009. Letters. Rapid responses to research. BMJ, 339, b2587. URL: http://www.bmj.com/cgi/eletters/339/jul09_1/b2587 (accessed 09.18.2009).
Jørgensen, K., & Gøtzsche, P. 2009. Overdiagnosis in publicly organised mammography screening programmes: Systematic review of incidence trends. BMJ, 339, b2587. URL (abstract): http://www.bmj.com/cgi/content/abstract/339/jul09_1/b2587 (accessed 09.18.2009).
3 Phillips, R. 2008. Breast self-exam. URL: http://www.webmd.com/menopause/guide/breast-self-exam (accessed 08.17. 2009).
4 Kösters, J., & Gøtzsche, P. 2003. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst. Rev. (2), CD003373. Review. URL (includes podcast): http://www.cochrane.org/reviews/en/ab003373.html (accessed 09.18.2009).
5 Fournier, A., et al. 2008. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res. Treat., 107 (1), 103–111. URL: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17333341 (accessed 09.18.2009).
Fournier, A., et al. 2008. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J. Clin. Oncol., 26 (8), 1260–1268. URL: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=18323549 (accessed 09.18.2009).
Fabre, A., et al. 2007. Oral progestagens before menopause and breast cancer risk. Br. J. Cancer, 96 (5), 841–844. URL: http://www.nature.com/bjc/journal/v96/n5/abs/6603618a.html (accessed 09.18.2009).
Campagnoli, C., et al. 2005. Pregnancy, progesterone and progestins in relation to breast cancer risk. J. Steroid Biochem. Mol. Biol., 97 (5), 441–450. URL: http://www.ncbi.nlm.nih.gov/pubmed/16249080 (accessed 09.18.2009).
Fournier, A., et al. 2005. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N–EPIC cohort. Int. J. Cancer, 114 (3), 448–454. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15551359 (accessed 02.21.2007).
Stahlberg, C., et al. 2004. Increased risk of breast cancer following different regimens of hormone replacement therapy frequency used in Europe. Int. J. Cancer, 109 (5), 721–727. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/14999781 (accessed 09.18.2009).
De Lignieres, B., et al. 2002. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric, 5 (4), 332–340. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/12626212 (accessed 09.18.2009).
Foidart, J., et al. 1998. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil. Steril., 69 (5), 963–969. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/9591509 (accessed 09.18.2009).
References on breast health risk factors
a Bradlow, H. 2008. Review. Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. In Vivo, 22 (4), 441–445. Review. URL: http://www.ncbi.nlm.nih.gov/pubmed/18712169 (accessed 09.26.2008).
Kunimasa, K., et al. 2008. Indole-3-carbinol suppresses tumor-induced angiogenesis by inhibiting tube formation and inducing apoptosis. Biosci. Biotechnol. Biochem., 72 (8), 2243–2246. URL: http://www.ncbi.nlm.nih.gov/pubmed/18685185 (accessed 09.26.2008).
b John, E., et al. 1999. Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev., 8 (5), 399–406. URL: http://cebp.aacrjournals.org/content/8/5/399.long (accessed 09.18.2009).
c Garland, C., et al. 2009. Vitamin D for cancer prevention: Global perspective. Ann. Epidemiol., 19 (7), 468–483. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19523595 (accessed 08.20.2009).
Peterlik, M., et al. 2009. Anticancer Res., 29 (9), 3687–3698. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19667166 (accessed 08.20.2009).
d Kuper, H, et al. 2009. Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol. Biomarkers Prev. [Epub ahead of print.] URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19690185 (accessed 08.20.2009).
e Crew, K., et al. 2009. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev. Res., 2 (6), 598–604. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19470790 (accessed 10.14.2009).
Rejnmark, L., et al. 2009. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: A nested case-control study. Cancer Epidemiol. Biomarkers Prev., 18 (10), 2655–2660. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19789365 (accessed 10.14.2009).
f Morrison, J., et al. 2009. Effects of dried cruciferous powder on raising 2/16 hydroxyestrogen ratios in premenopausal women. Altern. Ther. Health Med., 15 (2), 52–53. URL (no abstract available): http://www.ncbi.nlm.nih.gov/pubmed/19284183 (accessed 08.20.2009).
Skupinska, K., 2009. The effect of isothiocyanates on CYP1A1 and CYP1A2 activities induced by polycyclic aromatic hydrocarbons in Mcf7 cells. Toxicol. In Vitro, 23 (5), 763–771. URL (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19362136 (accessed 08.20.2009).
Return to:
Top breast concerns in menopause
Original Publication Date: 10/05/2009
Last Modified: 02/16/2010
Principal Author: Marcella Sweet